These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 18799033)

  • 1. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
    Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
    Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and toxicity of trastuzumab combined vinorelbine in 21 patients with HER2 overexpressing metastatic breast cancer].
    Zhou NN; Liu DG; Teng XY; Jiang WQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1707-9. PubMed ID: 18819904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].
    Guo J; Xu B; Ma F; Fan Y; Yuan P; Wang J; Cai R; Li Q; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):372-6. PubMed ID: 25030594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
    Ishida T; Kiba T; Takeda M; Matsuyama K; Teramukai S; Ishiwata R; Masuda N; Takatsuka Y; Noguchi S; Ishioka C; Fukushima M; Ohuchi N
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):361-9. PubMed ID: 19082596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
    Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
    Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
    Julka PK; Sharma DN; Mukhopadhyay P; Rath GK
    Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):115-8. PubMed ID: 15074734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
    Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
    Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
    Sato N; Sano M; Tabei T; Asaga T; Ando J; Fujii H; Yamamoto N; Kurosumi M; Inoue K; Kimura M
    Breast Cancer; 2006; 13(2):166-71. PubMed ID: 16755112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].
    Kagawa N; Fukuda Y; Arai H; Sasada T; Yamashita M; Komekami Y; Matsugu Y; Nakahara H; Tanaka T
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1081-5. PubMed ID: 16912526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
    Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
    Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F; Pribylova O; Zimovjanova M; Pazdrova G; Safanda M; Zemanova M; Petruzelka L
    Bull Cancer; 2004 Oct; 91(10):E279-83. PubMed ID: 15582895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].
    Kimura M; Sano M; Tabei T; Asaga T; Ando J; Fujii H; Yamamoto N; Kurosumi M
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):335-9. PubMed ID: 15791816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
    Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.